PriceTargets.com logo

NeurAxis - NRXS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$3.80 As of 09/29/2023 01:00 AM ET
▼ -0.27 (-6.63%)

This chart shows the closing price for NRXS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New NeurAxis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NRXS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NRXS

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for NeurAxis in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $3.80.

This chart shows the closing price for NRXS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in NeurAxis. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/7/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/6/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/4/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/2/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/2/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/1/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/29/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/23/2023Westpark CapitalInitiated CoverageBuyLow
(Data available from 9/30/2018 forward)

News Sentiment Rating

0.47 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/4/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/2/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/2/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/1/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/31/2023
  • 4 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
9/30/2023

Current Sentiment

  • 4 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

NeurAxis logo
NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.
Read More

Today's Range

Now: $3.80
Low: $3.31
High: $5.20

50 Day Range

MA: N/A

52 Week Range

Now: $3.80
Low: $3.19
High: $6.93

Volume

153,353 shs

Average Volume

40,457 shs

Market Capitalization

$18.93 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of NeurAxis?

The following sell-side analysts have issued stock ratings on NeurAxis in the last twelve months: Westpark Capital.
View the latest analyst ratings for NRXS.

What is the current price target for NeurAxis?

0 Wall Street analysts have set twelve-month price targets for NeurAxis in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for NeurAxis in the next year.
View the latest price targets for NRXS.

What is the current consensus analyst rating for NeurAxis?

NeurAxis currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NRXS will outperform the market and that investors should add to their positions of NeurAxis.
View the latest ratings for NRXS.

What other companies compete with NeurAxis?

Other companies that are similar to NeurAxis include electroCore, Precision Optics, Soleno Therapeutics, BioSig Technologies and Vivani Medical. Learn More about companies similar to NeurAxis.

How do I contact NeurAxis' investor relations team?

The company's listed phone number is (812) 689-0791 and its investor relations email address is [email protected]. The official website for NeurAxis is neuraxis.com. Learn More about contacing NeurAxis investor relations.